What TempraMed does

TempraMed Inc. designs, manufactures, and sells a portfolio of temperature-regulated medication storage devices under the VIVI brand for patients using injectable medications. The company's core product, VIVI Cap, is a thermal insulin pen carrying case using patented space-grade insulation combined with Phase Change Material (PCM) heat absorption that passively maintains insulin and GLP-1 medications within safe temperature (36–86°F) without batteries, water, ice, or charging. The portfolio extends to VIVI Epi (epinephrine auto-injector shield), VIVI Med (vial/ biologic case), and the recently launched VIVI Cap Smart (Bluetooth-connected version with mobile app, injection tracking, dose reminders, and shareable reports for healthcare providers). The flagship technology is supported by 9 global patents (notably granted in China in March 2026 and Brazil in April 2026 covering VIVI Box through 2039), FDA and CE registration, and a peer-reviewed clinical study published in Expert Opinion on Drug Delivery demonstrating an 86% time-in-range glycemic outcome vs. 82% without thermal protection.

TempraMed monetizes primarily through one-time hardware sales at an MSRP of $168/unit, with a B2B pharmacy starter pack pricing of $75/unit per 5-unit bundle and a subscription/annual membership pricing (~30% savings vs. monthly) introduced with VIVI Cap Smart. Distribution combines direct-to-consumer e-commerce (tempramed.com with HSA/FSA support), major US retail and pharmacy channels (CVS, Walmart, Walgreens, Amazon, McKesson, Humana, US Department of Veteran Affairs), large healthcare systems in Israel (Super-Pharm, Maccabi Healthcare Services covering 2.8 million insured members), and seven international distribution agreements covering Turkey, Benelux, South Korea, Panama, Saudi Arabia, and Brazil. Go-to-market also includes a physician engagement platform (FrontrowMD with 275+ recommending clinicians) and a strategic media partnership with Dr. Phil's Envoy Media providing access to ~19M monthly viewers.

The company operates as a publicly traded entity on the Canadian Securities Exchange under the symbol VIVI (IPO October 2025) and Frankfurt Stock Exchange (November 2025), with primary entity TempraMed Ltd. (Israel) and US operations headquartered in Sammamish, Washington, plus a Texas distribution warehouse and a Florida manufacturing facility opened in December 2025 with ~1M units/year capacity. Leadership includes Founder/CEO Ron Nagar (serial medical device entrepreneur and former InsuLine Medical and Glucon co-founder), Co-Founder/COO Elina Nagar, Executive Chairman Ilan Cohen, CFO Gabi Kabazo, and CFO Israel Shay Levin, supported by a Scientific Advisory Board featuring diabetes research luminaries including Prof. Dr. Lutz Heinemann. Approximately 100,000+ units have been sold to date with a ~30% repeat purchase rate, against a stated addressable market of 160 million patients and $30 billion in global opportunity; 2024 revenue was US$2.2M with management projecting ~US$15M for 2026.

Name

TempraMed

Legal name

TempraMed Inc.

Website

https://tempramed.com/

Company type

Public

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

TempraMed designs and sells FDA/CE-registered VIVI thermal-protection cases for insulin and GLP-1 pens, epinephrine auto-injectors, vials, and biologics, using patented space-grade insulation and Phase Change Material technology for patients managing diabetes, severe allergies, and specialty medication regimens globally.

Ownership category

akta.pro rank

Product category

Temperature-Controlled Medical Storage Devices

NAICS

Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Personal Medical Devices & Home Diagnostics (Thermometers, Blood Pressure Monitors, Glucose Meters, Rapid Tests) (CRADAMAK)

Keywords

• Insulin pen protection
• Temperature-controlled medication storage
• Cold chain medical devices
• GLP-1 pen cases
• EpiPen temperature shield

Headquarters

HQ city

Sammamish

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Marketing or Sales, Personnel, Technology or R&D, Infrastructure

Revenue model

1. Hardware Sales - VIVI Cap: One-time sale of VIVI Cap thermal insulin pen protection device; reusable for years, priced at $168/unit MSRP for B2B/pharmacy
2. Hardware Sales - VIVI Epi: One-time sale of VIVI Epi EpiPen temperature shield for epinephrine auto-injectors
3. Hardware Sales - VIVI Med: One-time sale of VIVI Med medication temperature protection case for vials and injectable medications including biologics and GLP-1s
4. Hardware + Subscription - VIVI Cap Smart: Connected device combining thermal protection with digital tracking; introduces subscription-based revenue model alongside hardware sales for app features and data reports
5. Recurring Revenue from Repeat Purchases: ~30% of customers make repeat purchases; loyalty program with points-based rewards

Pricing tiers

Go-to-market motion5 records

Distribution channels11 records

Marketing channels8 records

Core offering

TempraMed designs, manufactures, and sells the VIVI line of medical-device carrying cases that passively maintain injectable medications within their safe temperature range (36–86°F) using patented space-grade insulation and self-regenerating Phase Change Material. The portfolio includes VIVI Cap and VIVI Cap Smart (insulin/GLP-1 pen cases), VIVI Epi (epinephrine auto-injector shield), and VIVI Med (vial and biologic case), with the connected VIVI Cap Smart adding Bluetooth injection tracking via a mobile app.

Product overview

TempraMed offers a portfolio of temperature-regulated medication storage products under the VIVI brand. The core offerings include VIVI Cap (insulin pen protection), VIVI Cap Smart (digital version with tracking), VIVI Epi (EpiPen protection), and VIVI Med (vial/biologic protection). The products use patented space-grade thermal insulation technology with phase change material for passive temperature control. VIVI Cap Smart adds digital health features including Bluetooth connectivity, injection tracking, and mobile app integration. Upcoming products include VIVI Box (multi-medication platform) and VIVI Cool 8C (drug storage). All products are FDA and CE registered, manufactured in the USA, and designed for the 'last mile' of medication temperature control from pharmacy to patient use.

Differentiator

Problem solved

Functional benefit

Brands

• VIVI Cap Smart: Digitally connected temperature protection device for insulin and GLP-1 pens with injection tracking and mobile app connectivity
• VIVI Cap
• VIVI Epi
• VIVI Med
• VIVI Box
• VIVI Cool 8C

Products and services

• VIVI Cap Thermal insulin pen carrying case that protects insulin and GLP-1 pens from extreme temperatures using patented space-grade insulation and phase change material; maintenance-free, no batteries, works 24/7/365.
• VIVI Cap Smart Advanced digital version of VIVI Cap combining space-grade thermal protection with injection-time tracking, Bluetooth connectivity, and a mobile application for dose logging, reminders, and shareable PDF/CSV health-provider reports.
• VIVI Epi EpiPen temperature shield that protects epinephrine auto-injectors from extreme temperatures and light to ensure efficacy during anaphylaxis; FDA- and CE-registered, maintenance-free.
• VIVI Med Temperature protection case for vials and injectable medications including biologics, GLP-1s, Humira, and blood glucose test strips; holds up to 2 vials and is reusable for years.
• VIVI Box Upcoming multi-medication storage platform with thermal insulation and smart-monitoring architecture for continuous temperature protection, portable travel functionality, and cloud-based content tracking across Brazil, China, and other markets.

Quantifiable outcome

• 86% time-in-range vs 82% without thermal protection (clinical study in Greece)
• +4 more outcomes

Named customers11 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

13 partnerships are on record, tiered major, core, flagship and minor.

• Rawafed Health International CompanymajorChannel Partner/ Reseller/ Distributor · 26 June 2026Non-binding LOI for 5-year exclusive distribution arrangement in Saudi Arabia with minimum purchase orders of approximately US$3.1 million. Exclusivity contingent upon Saudi FDA regulatory approval and first commercial order of at least US$170,000. Initial product coverage is VIVI Cap targeting Saudi Arabia's 5.34 million adults with diabetes.
• TEM Consulting International S.A.coreChannel Partner/ Reseller/ Distributor · 30 March 2026Non-binding LOI for distribution of VIVI temperature-regulated medication storage products across Panama. Definitive agreement expected within 90 days. Partnership targets Panama's growing diabetes and obesity markets with initial focus on urban, higher-income private-pay patients.
• FrontrowMDmajorGTM or Marketing Partner · 26 February 2026Physician engagement platform partnership launched December 2025 where over 275 physicians across the United States recommend VIVI Cap to patients. Positions product within clinical workflow to drive patient adoption beyond traditional pharmacy channels.
• Super-PharmmajorChannel Partner/ Reseller/ Distributor · 10 February 2026National rollout of TempraMed's temperature-protection medication products across Super-Pharm, Israel's largest pharmacy chain. Gives TempraMed access to millions of consumers through one of Israel's most trusted healthcare platforms. Products available across Super-Pharm's nationwide locations including VIVI Cap and VIVI Epi.
• Maccabi Healthcare ServicesmajorChannel Partner/ Reseller/ Distributor · 6 February 2026National brick-and-mortar and online pharmacy rollout through Maccabi Healthcare Services, Israel's second-largest HMO serving over 2.8 million insured members. First in-store and online sales milestone demonstrating scale execution within large healthcare system.
• Dr. Phil's Envoy MediaflagshipGTM or Marketing Partner · 2 February 2026Strategic media partnership securing exclusive title sponsorship of 44-minute television special on prescription medication safety airing May 2026. Provides access to approximately 19 million monthly viewers across broadcast TV, podcasts, YouTube, and social media platforms. TempraMed receives full content usage rights for digital acquisition, enterprise sales, and international expansion.
• Mavens Co. LtdcoreChannel Partner/ Reseller/ Distributor · 2 January 2026Expanded distribution partnership with Mavericks Co. Ltd (Mavens) in South Korea supporting growth across Asia. Partnership strengthens TempraMed's footprint in South Korea's healthcare ecosystem targeting pharmacies, hospitals, and clinics. South Korean diabetes medications sector valued at nearly US$1 billion.
• Professor Dr. Lutz HeinemannminorStrategic or Co-development Partner · 10 December 2025Appointment to Scientific Advisory Board. Renowned diabetes researcher providing expertise in diabetes and medication stability science to support TempraMed's thermal-stability technology expansion.
• Salomo ExecutivecoreChannel Partner/ Reseller/ Distributor · 5 December 2025Distribution partnership expanding into Western Europe covering Benelux region (Netherlands, Belgium, and Luxembourg). Aims to increase access to TempraMed's temperature-sensitive medication storage products amid rising diabetes prevalence.
• Dolfin SağlıkcoreChannel Partner/ Reseller/ Distributor · 2 December 2025Exclusive distribution agreement to market and sell VIVI line of medication temperature-stabilizing products in Turkey. Capitalizes on Turkey's high diabetes prevalence where about 10 million people have diabetes.
• Guri A.A.O.majorChannel Partner/ Reseller/ Distributor · 26 November 2025Exclusive distribution agreement with leading consumer health distributor in Israel. Supports TempraMed's shift from online direct-to-consumer sales towards large retail pharmacy networks and medical payers globally.
• bullVestor Medien GmbHminorGTM or Marketing Partner · 18 November 2025Marketing services agreement associated with Frankfurt Stock Exchange listing. Involves fee of approximately €130,000 for investor awareness services.
• Beyond Type 1minorGTM or Marketing Partner · 27 October 2025In-kind partnership supporting 55 runners, many living with diabetes, at the 2025 TCS New York City Marathon. Provides temperature-protective solutions for runners' medications during the race.

Scale indicators10 records

Recent moves10 records

Expansion highlights7 records

Direct peers

• Frio UK: Frio UK makes evaporative cooling wallets and pouches specifically designed to keep insulin and other temperature-sensitive medications cool without refrigeration. They are a direct competitor to TempraMed's VIVI Cap, addressing the same 'last mile' cold-chain problem for insulin users via a different cooling mechanism (evaporation vs. PCM).
• 4AllFamily: 4AllFamily produces insulated medication travel cases and cooling pouches for insulin, GLP-1 medications, and biologics, directly overlapping with TempraMed's VIVI Cap and VIVI Med products. They compete for the same insulin/GLP-1 patient demographic with a similar DTC e-commerce model.
• Medicool: Medicool manufactures insulin protector cases and cooling wallets for diabetes patients, including products designed for portable temperature control of insulin pens and vials. They are a legacy direct competitor in the insulin storage category that TempraMed is disrupting with newer PCM-based technology.

Broad incumbents

• Becton Dickinson (BD): Becton Dickinson is a global medical technology giant with a broad portfolio of drug delivery devices (including insulin pens, auto-injectors, and prefilled syringes) and medication management accessories. While not focused on temperature protection specifically, BD has the scale and distribution to enter TempraMed's niche.
• Medtronic: Global medical device leader with diabetes (insulin pumps, CGM) and broader medical device portfolios. Susan Alpert, former Senior VP Global Regulatory Affairs at Medtronic, sits on TempraMed's advisory board, highlighting the potential incumbent threat in medication management devices.

Emerging players

• Apex Medical Corporation: Apex Medical develops medical device accessories for chronic disease management, with overlap in medication storage and portability products. While broader in scope, they are an emerging player in adjacent patient-focused medical device categories.
• Ypsomed: Swiss-based manufacturer of insulin pens, auto-injectors, and smart injection devices. Their mySmartPilot and YpsoMate platforms overlap with TempraMed's VIVI Cap Smart in addressing smart injection tracking for diabetes patients, though Ypsomed focuses on delivery rather than temperature protection.

Others

• Novo Nordisk: The world's largest insulin manufacturer and major GLP-1 producer (Ozempic, Wegovy). While not a direct competitor, Novo Nordisk could choose to bundle or co-promote temperature protection accessories with their injectable medications, representing both a potential partner and a threat to TempraMed's market position.
• Eli Lilly: Major GLP-1 manufacturer (Mounjaro, Zepbound) and insulin producer. As with Novo Nordisk, Lilly represents both a potential partner opportunity and a competitive threat, as they could develop proprietary or branded temperature protection solutions for their injectable portfolio.
• Insulet: Insulet manufactures the Omnipod insulin patch pump, a leading insulin delivery system. While not directly competing in temperature protection, Insulet targets the same diabetes patient demographic and represents an adjacent diabetes management technology competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Subsidiaries1 record

Funding overview

Funding rounds4 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TempraMed